UFIS-SWE-IG
0.1.0 - ci-build

UFIS-SWE-IG, published by UNICOM. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/ufis-swe-ig/ and changes regularly. See the Directory of published versions

Example RegulatedAuthorization: Levaxin-200mg-Tablet-SE-BS-RA

Generated Narrative: RegulatedAuthorization Levaxin-200mg-Tablet-SE-BS-RA

identifier: http://ema.europa.eu/fhir/marketingAuthorizationNumber/21055

subject: MedicinalProductDefinition: identifier = http://ema.europa.eu/fhir/mpId#SE-XXXXXXXXX-00021055,http://ema.europa.eu/fhir/eurdId#1860; domain = Human use; status = Current; combinedPharmaceuticalDoseForm = Tablet; indication = Hypotyreos av alla former t ex vid autoimmun tyreoidit, efter radiojod- och kirurgisk terapi av hypertyreos och vid progressiv oftalmopati när den är förenad med hypotyreos. Som tillägg till tyreostatika vid långtidsbehandling av hypertyreos och vid preoperativ kombinationsbehandling av hypertyreos. Tyreoideacancer. Myxödemkoma.; legalStatusOfSupply = Medicinal product subject to medical prescription; classification = levothyroxine sodium

type: Marketing Authorisation

region: Kingdom of Sweden

status: Valid

statusDate: 2005-09-16

holder: Organization Orifarm Healthcare A/S

Cases

-TypeDate[x]
*First Authorisation2005-09-16